AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2108113 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglycosides given once daily (4.5 mg/kg bodyweight/day)
Number of subjects: 60
Study 2108113 — intervention group
Group type: COMPARATOR
Intervention: Aminoglycosides given three times a day (4.5 mg/kg bodyweight/day)
Number of subjects: 60
Study 2108113 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin three times a day
Number of subjects: 60
Study 2108113 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin once daily
Number of subjects: 60
Study 2108113 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrotoxicity across all treatment groups
Number of subjects: 60
Study 2108113 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglycosides once daily
Number of subjects: 60
Study 7387817 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 microgram i.v. naloxone
Number of subjects: 29
Study 7387817 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 microgram i.v. naloxone
Number of subjects: 29
Study 7387817 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microgram i.m. naloxone
Number of subjects: 29
Study 30716477 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically estimated 25(OH)D concentration increase of 20 nmol/L for BE risk
Number of subjects: 17159
Study 30716477 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically estimated 25(OH)D concentration increase of 20 nmol/L for EAC risk
Number of subjects: 17159
Study 29227571 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin XR
Number of subjects: 532
Study 29227571 — intervention group
Group type: COMPARATOR
Intervention: Metformin IR
Number of subjects: 532
Study 27741153 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment with Bifidobacterium breve BR03, B. breve B632, and Lactobacillus delbrueckii subsp. delbrueckii LDD01 at a concentration of 10 viable cells/strain/daily dose (5 drops)
Number of subjects: 4000
Study 27741153 — intervention group
Group type: COMPARATOR
Intervention: Control group of 2000 babies from the same community
Number of subjects: 4000
Study 25172877 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated insulin pump system in adolescent subgroup
Number of subjects: 35
Study 22965989 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin plus 81 mg of aspirin (n=28)
Number of subjects: 56
Study 22965989 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 325 mg only (n=28)
Number of subjects: 56
Study 20687826 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline treatment for at least 2 weeks
Number of subjects: 50
Study 18076250 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruce protocol
Number of subjects: 30
Study 18076250 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Astrand protocol
Number of subjects: 30
Study 15618332 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric portion of the drop jumps
Number of subjects: 70
Study 15618332 — intervention group
Group type: EXPERIMENTAL
Intervention: Counter movement jump
Number of subjects: 70
Study 15618332 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping jacks
Number of subjects: 70
Study 15618332 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop jump from 10 cm
Number of subjects: 70
Study 11948829 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) preparation
Number of subjects: 22
Study 11948829 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 22
Study 9465357 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact group (received three brief telephone calls at 2 weeks, 2 months, and 4 months after training)
Number of subjects: 198
Study 9465357 — intervention group
Group type: COMPARATOR
Intervention: Noncontact group (did not receive reinforcement contact)
Number of subjects: 198
Study 9465357 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact group
Number of subjects: 198
Study 9465357 — intervention group
Group type: COMPARATOR
Intervention: Noncontact group
Number of subjects: 198
Study 9465357 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients identified as ready to quit smoking
Number of subjects: 198
Study 7620843 — intervention group
Group type: EXPERIMENTAL
Intervention: One-group conditions (judging group alone)
Number of subjects: 65
Study 7620843 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-group conditions (judging both groups)
Number of subjects: 65
Study 7620843 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-group conditions with non-stereotypic traits
Number of subjects: 65
Study 7620843 — intervention group
Group type: EXPERIMENTAL
Intervention: Second experiment (N = 297) with additional manipulation of trait favourableness
Number of subjects: 65
Study 1974071 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem 25-150 mg daily
Number of subjects: 24
Study 1974071 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 1-6 mg daily
Number of subjects: 24
Study 1974071 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem 25 mg
Number of subjects: 24
Study 1974071 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem 50 mg
Number of subjects: 24
Study 1974071 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam 2 mg
Number of subjects: 24
Study 1974071 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpidem 100 mg
Number of subjects: 24
Study 407056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 28
Study 407056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7262175 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prednisolone injection at three different doses
Number of subjects: 0
Study 7262175 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone at five different doses
Number of subjects: 0
Study 7262175 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intravenous and oral administration of prednisolone
Number of subjects: 0
Study 31365188 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC EZE/ROS5
Number of subjects: 0
Study 31365188 — intervention group
Group type: COMPARATOR
Intervention: Individual ROS tablets
Number of subjects: 0
Study 30559162 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient precision-exercise intervention group
Number of subjects: 200
Study 30559162 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group
Number of subjects: 200
Study 27328378 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV warm-up
Number of subjects: 20
Study 27328378 — intervention group
Group type: COMPARATOR
Intervention: no-WBV warm-up
Number of subjects: 20
Study 26958466 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for chronic pain, 11-week duration
Number of subjects: 19
Study 26958466 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 19
Study 26958466 — intervention group
Group type: COMPARATOR
Intervention: Educational materials (active control)
Number of subjects: 19
Study 22797843 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced communication therapy specific to aphasia or dysarthria, offered by speech and language therapists for up to four months.
Number of subjects: 170
Study 22797843 — intervention group
Group type: COMPARATOR
Intervention: Attention control (unstructured social contact) provided by employed visitors.
Number of subjects: 170
Study 22797843 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced communication therapy
Number of subjects: 170
Study 22797843 — intervention group
Group type: COMPARATOR
Intervention: Attention control (unstructured social contact)
Number of subjects: 170
Study 21302487 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Danshen Dripping Pill (CDDP) 10 pills, thrice daily for 18 months
Number of subjects: 108
Study 21302487 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Danshen Dripping Pill (CDDP)
Number of subjects: 108
Study 21302487 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 0.1 g, once daily for 18 months
Number of subjects: 108
Study 21302487 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E 0.1 g, twice daily for 18 months
Number of subjects: 108
Study 17057393 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 153
Study 17057393 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 153
Study 17057393 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo (Control)
Number of subjects: 153
Study 15707755 — intervention group
Group type: EXPERIMENTAL
Intervention: Kothala Himbutu tea for 3 months
Number of subjects: 51
Study 15707755 — intervention group
Group type: EXPERIMENTAL
Intervention: Kothala Himbutu tea
Number of subjects: 51
Study 15707755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 12059064 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation with 0.1 mg/kg of midazolam
Number of subjects: 8
Study 12059064 — intervention group
Group type: COMPARATOR
Intervention: No sedation (control group)
Number of subjects: 8
Study 10460138 — intervention group
Group type: EXPERIMENTAL
Intervention: Attempting to break the fall by using an arm (slap condition)
Number of subjects: 0
Study 10460138 — intervention group
Group type: COMPARATOR
Intervention: Falling with the body tensed (tensed condition)
Number of subjects: 0
Study 10460138 — intervention group
Group type: COMPARATOR
Intervention: Falling with the body relaxed (relaxed condition)
Number of subjects: 0
Study 7605188 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol based bisacodyl suppositories (PGB)
Number of subjects: 26
Study 7605188 — intervention group
Group type: COMPARATOR
Intervention: Hydrogenated vegetable oil based bisacodyl suppositories (HVB)
Number of subjects: 26
Study 2371435 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms inhaled salbutamol
Number of subjects: 7
Study 2371435 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 micrograms inhaled formoterol
Number of subjects: 7
Study 2371435 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 micrograms inhaled formoterol
Number of subjects: 7
Study 2371435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 349841 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of nitrous oxide in the lower extremities as part of conservative treatment.
Number of subjects: 40
Study 349841 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nitrous oxide injection).
Number of subjects: 40
Study 31699572 — intervention group
Group type: EXPERIMENTAL
Intervention: Bihemispheric tDCS combined with physical therapy (PT) and occupational therapy (OT)
Number of subjects: 32
Study 31699572 — intervention group
Group type: COMPARATOR
Intervention: Sham bihemispheric tDCS combined with physical therapy (PT) and occupational therapy (OT)
Number of subjects: 32
Study 29608733 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapist-administered physical activity intervention including a wearable activity tracking device, individualized step goals, and face-to-face feedback
Number of subjects: 125
Study 29608733 — intervention group
Group type: COMPARATOR
Intervention: Standardized physical therapy alone after TKR
Number of subjects: 125
Study 27072443 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed practice module
Number of subjects: 58
Study 27072443 — intervention group
Group type: COMPARATOR
Intervention: Blocked practice module
Number of subjects: 58
Study 24058189 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (oral dose)
Number of subjects: 11
Study 24058189 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 11
Study 23707270 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab (5 or 10mg intravenous, up to 2 doses in 8-week intervals)
Number of subjects: 610
Study 23707270 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone (10 to 40 mg every 12 hours)
Number of subjects: 610
Study 23707270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study 20433721 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation with polyethylene glycol (Group A)
Number of subjects: 244
Study 20433721 — intervention group
Group type: COMPARATOR
Intervention: No mechanical bowel preparation (Group B)
Number of subjects: 244
Study 18657146 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (30 mug ethinyl estradiol and 150 mug levonorgestrel) administered daily for 21 days starting on the first day of the menstrual cycle.
Number of subjects: 82
Study 18657146 — intervention group
Group type: COMPARATOR
Intervention: Natural menstrual cycle (control group).
Number of subjects: 82
Study 18657146 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (COC) in the first week of the cycle.
Number of subjects: 82
Study 18657146 — intervention group
Group type: COMPARATOR
Intervention: Natural cycle in the first week.
Number of subjects: 82
Study 16825272 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 157
Study 16825272 — intervention group
Group type: COMPARATOR
Intervention: Travoprost 0.004%
Number of subjects: 157
Study 12810896 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia group using the interactive program to learn about home safety
Number of subjects: 126
Study 12810896 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional learning group reading booklets on home safety
Number of subjects: 126
Study 12810896 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no instruction on safety
Number of subjects: 126
Study 10743861 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil-containing antiseptic mouthrinse (Listerine Antiseptic)
Number of subjects: 29
Study 10743861 — intervention group
Group type: COMPARATOR
Intervention: Sterile water control
Number of subjects: 29
Study 9382217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanov
Number of subjects: 42
Study 9382217 — intervention group
Group type: COMPARATOR
Intervention: Tramal
Number of subjects: 42
Study 8473538 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAUN electric toothbrush (D5)
Number of subjects: 60
Study 8473538 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAUN electric toothbrush (D3)
Number of subjects: 60
Study 8473538 — intervention group
Group type: COMPARATOR
Intervention: manual toothbrush (M)
Number of subjects: 60
Study 3513357 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) at a dose of 30 ng/kg . min
Number of subjects: 15
Study 3513357 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 15
Study 29287664 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) in combination with Contingency Management (CM)
Number of subjects: 0
Study 29287664 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT+CM in combination with modafinil
Number of subjects: 0
Study 27799387 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 14
Study 27799387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 25367544 — intervention group
Group type: EXPERIMENTAL
Intervention: individual‐ESI
Number of subjects: 82
Study 25367544 — intervention group
Group type: COMPARATOR
Intervention: group‐ESI
Number of subjects: 82
Study 22369682 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose proton pump inhibitors (80 mg bolus, followed by pantoprazole 8 mg/h infusion, n = 100)
Number of subjects: 201
Study 22369682 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose proton pump inhibitors (pantoprazole 40 mg bolus daily, n = 101)
Number of subjects: 201
Study 20061123 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide 200mg/day
Number of subjects: 647
Study 20061123 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide 400mg/day
Number of subjects: 647
Study 20061123 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide 800mg/day
Number of subjects: 647
Study 20061123 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufinamide 1600mg/day
Number of subjects: 647
Study 20061123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 647
Study 18947287 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartz‐tungsten‐halogen (QTH) curing unit
Number of subjects: 45
Study 18947287 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma arc curing (PAC) unit
Number of subjects: 45
Study 18947287 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-emitting diode (LED) unit
Number of subjects: 45
Study 18947287 — intervention group
Group type: COMPARATOR
Intervention: Conventional halogen light (Control)
Number of subjects: 45
Study 15795027 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative learning and case study (n=31)
Number of subjects: 123
Study 15795027 — intervention group
Group type: COMPARATOR
Intervention: Lecture and large group case study (n=46)
Number of subjects: 123
Study 15795027 — intervention group
Group type: COMPARATOR
Intervention: Lecture only (n=24)
Number of subjects: 123
Study 15795027 — intervention group
Group type: COMPARATOR
Intervention: Lecture and occasional use of non-cooperative learning groups (n=22)
Number of subjects: 123
Study 12576970 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol administration for >72 hrs (group 1)
Number of subjects: 30
Study 12576970 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol administration for 24 to 48 hrs (group 2)
Number of subjects: 30
Study 12576970 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 3)
Number of subjects: 30
Study 11215153 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 12
Study 11215153 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (7.5 mg)
Number of subjects: 12
Study 11215153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8660168 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 26
Study 8660168 — intervention group
Group type: COMPARATOR
Intervention: Ganciclovir
Number of subjects: 26
Study 2002646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A therapy (10 mg/kg/day)
Number of subjects: 16
Study 2002646 — intervention group
Group type: COMPARATOR
Intervention: Blood transfusions (3 to 5 third-party transfusions at two weekly intervals)
Number of subjects: 16
Study 6408031 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual dietetic counselling
Number of subjects: 36
Study 6408031 — intervention group
Group type: EXPERIMENTAL
Intervention: Group dietetic counselling
Number of subjects: 36
Study 6408031 — intervention group
Group type: EXPERIMENTAL
Intervention: Group dietetic counselling with behaviour modification
Number of subjects: 36
Study 30421537 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (G/P) 8-week treatment
Number of subjects: 693
Study 30421537 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (G/P) 12-week treatment
Number of subjects: 693
Study 30421537 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (G/P) 16-week treatment
Number of subjects: 693
Study 29451696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (arm 1)
Number of subjects: 172
Study 29451696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed and bevacizumab (arm 2)
Number of subjects: 172
Study 29451696 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed, carboplatin, and bevacizumab (arm 3)
Number of subjects: 172
Study 27629490 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde intubation (RI)
Number of subjects: 100
Study 27629490 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 100
Study 24854809 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad mood condition
Number of subjects: 85
Study 24854809 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral mood condition
Number of subjects: 85
Study 22669067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) including hypnosis; 6-session program
Number of subjects: 72
Study 22669067 — intervention group
Group type: COMPARATOR
Intervention: Conservative standard treatment for TMD
Number of subjects: 72
Study 20472510 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily
Number of subjects: 401
Study 20472510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 18323230 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-fentanyl
Number of subjects: 0
Study 18323230 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptic anaesthesia
Number of subjects: 0
Study 15966131 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination inhaled corticosteroids and long acting beta agonists (ICS/LABA)
Number of subjects: 0
Study 12198062 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine
Number of subjects: 77
Study 12198062 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine plus clonidine 30 microg
Number of subjects: 77
Study 12198062 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine plus clonidine 60 microg
Number of subjects: 77
Study 10561258 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation (epirubicin 60 mg/m(2)) followed by adjuvant chemotherapy (epirubicin 90 mg/m(2) at 4-week intervals for five cycles)
Number of subjects: 220
Study 10561258 — intervention group
Group type: COMPARATOR
Intervention: Standard pelvic radiotherapy
Number of subjects: 220
Study 8607100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl icosapentatenoate (EPA: 1800 mg/day) for 4 weeks
Number of subjects: 115
Study 8607100 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 115
Study 1309115 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG (FSH:LH = 1:1) administered to 18 patients (group A)
Number of subjects: 37
Study 1309115 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified hMG (FSH:LH = 19:1) administered to 19 patients (group B)
Number of subjects: 37
Study 3918356 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg sodium cromoglycate aerosol
Number of subjects: 11
Study 3918356 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg sodium cromoglycate aerosol
Number of subjects: 11
Study 3918356 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg sodium cromoglycate aerosol
Number of subjects: 11